HRMY's Largest Beat in 4 Quarters Shadowed by Insider Sale
HRMY delivered its largest earnings beat in four quarters with Q2 EPS of $1.50, beating consensus by 30.5%, yet an insider reportedly plans to sell $230,000 in stock. The 6.3x forward P/E valuation an
HRMY Guidance Reaffirmed; Insider Plans $230K Sale
NEW YORK, September 5 —
Harmony Biosciences Holdings, Inc. (HRMY) delivered its largest earnings beat in four quarters and reaffirmed full-year guidance, yet an executive reportedly disclosed a plan to sell approximately $230,000 in stock at current prices. Short sellers hold 9.5% of the float. At 6.3x forward earnings, the market is running a different calculation than guidance implies.
- Q2 2026 EPS of $1.50 beat consensus by 30.5%; trailing 12-month revenue reached $0.96 billion, up 30.3% year-over-year.
- Forward P/E of 6.3x against 75.4% gross margins and $0.51 billion net cash, roughly 21% of market cap.
- An executive reportedly plans to sell approximately $230,000 in stock; short interest at 9.5% of the float.
A Beat Inside a Choppy Record
The beat, disclosed in HRMY's August 4 8-K filing, is real, but the context erodes conviction. Two quarters earlier, Harmony Biosciences Holdings, Inc. posted $0.57 against a $1.07 estimate, a 46.9% miss, followed by $0.79 against $0.93. The alternating pattern across four quarters looks less like an earnings inflection and more like structural volatility in a single-product franchise. WAKIX (pitolisant), the company's only approved therapy, treats excessive daytime sleepiness in adult narcolepsy patients via a novel mechanism, a narrow disease category where patient volumes and payer dynamics can swing quarterly results without signaling any fundamental shift.
A Valuation That Prices In Doubt
At 6.3x forward P/E against 30.3% revenue growth and 75.4% gross margins, HRMY trades as though the market expects the next miss before the next beat. The balance sheet does not invite that pessimism: $0.51 billion in net cash represents roughly 21% of the $2.46 billion market cap, and trailing free cash flow of $183 million implies a 7.4% FCF yield. Every dollar of HRMY's $0.96 billion in trailing revenue flows from WAKIX alone, meaning any durable growth debate eventually reduces to one drug in one indication, which is the structural argument the compressed multiple reflects.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| HRMY | $2.5B | 6.3x | +17.9% |
| KYMR | $9.7B | n/a | +171.1% |
| INBX | $1.8B | n/a | +316.4% |
| KROS | $224M | n/a | -28.2% |
| PCVX | $9.1B | n/a | +88.7% |
| RLAY | $4.2B | n/a | +368.2% |
The Signal the Insider Sent
The reported executive sale, alongside the existing short position, forms a pattern that gives credence to the miss streak preceding this beat. An analyst consensus of $47.36, about 12% above current prices, reflects a more constructive institutional view; a Phase 3 pitolisant trial for Prader-Willi Syndrome and an orexin 2 receptor agonist in development add optionality the compressed multiple does not appear to price. Stress-test the valuation at the DCF calculator. Q3 EPS resolves the setup: sustained near $1.50 validates the Q2 inflection; a reversion toward $0.79 confirms the bears were reading it right. Run the free Harmony Biosciences Holdings, Inc. deep-dive before that number arrives.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What were HRMY's Q2 2026 earnings results?
HRMY reported Q2 2026 EPS of $1.50, beating consensus estimates by 30.5%, marking the company's largest earnings beat in four quarters. Trailing 12-month revenue reached $0.96 billion, up 30.3% year-over-year, and the company reaffirmed full-year guidance.
Why is an insider selling HRMY stock after earnings beat?
An executive reportedly disclosed a plan to sell approximately $230,000 in stock at current prices. Combined with 9.5% short interest in the float, this insider sale forms a pattern suggesting market participants view the beat as an outlier rather than evidence of sustainable growth.
How is HRMY's stock valued relative to its growth?
HRMY trades at 6.3x forward P/E despite 30.3% revenue growth and 75.4% gross margins, implying the market expects future misses. The balance sheet includes $0.51 billion in net cash (21% of market cap) and a 7.4% free cash flow yield, but the compressed multiple reflects doubt about sustaining growth.
What is HRMY's only drug?
HRMY's entire business depends on WAKIX (pitolisant), which treats excessive daytime sleepiness in adult narcolepsy patients. All $0.96 billion in trailing revenue flows from this single drug in a narrow disease category where quarterly patient volumes and payer dynamics can swing results without signaling fundamental shifts.
What near-term developments could change HRMY's outlook?
Q3 earnings will determine if Q2 represents a sustained inflection or a reversion to the prior miss pattern. A Phase 3 trial for pitolisant in Prader-Willi Syndrome and an orexin 2 receptor agonist in development could expand the company beyond its single indication.
Harmony Biosciences shares hold near $42 after the company reaffirmed full-year guidance following a 30.5% Q2 EPS beat — yet an executive has disclosed a plan to sell approximately $230,000 worth of stock at current prices, while short sellers hold 9.5% of the float and the stock sits at just 6.3x forward earnings.